AstraZeneca entered the next-gen obesity race late and is moving through Phase 2b with a multi-asset strategy. The February 2026 $1.2 billion CSPC Pharmaceuticals collaboration brought in the two molecules that anchor the ASCEND program: AZD9550 (GLP-1 + glucagon dual agonist) and AZD6234 (selective amylin analog). Combined as a two-molecule fixed-dose combination, ASCEND is positioned as a 'triple mechanism' targeting fat-selective weight loss and organ protection — the safety-and-organ-protection lane that competitors leave open.
The broader obesity portfolio also includes eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 licensed from Eccogene that met primary endpoints in two Phase 2b trials — VISTA in 310 obesity patients (26-week weight loss) and SOLSTICE in 406 type-2 diabetes patients (26-week HbA1c versus semaglutide). AstraZeneca held back exact weight-loss numbers at the April 29 Q1 print, framing the molecule as 'very competitive,' with full data scheduled for ADA 2026 in June and a comprehensive Phase 3 program now committed. Macrocyclic peptide platform deals — including the early-2025 Syneron Bio collaboration worth up to $3.4 billion in milestones — extend the company's peptide-discovery footprint.
Stories here cover trial readouts, partnership economics, and the broader late-mover obesity strategy. See #azd9550, #azd6234, and #ascend.
AstraZeneca's eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 agonist licensed from Eccogene in 2023, met primary endpoints in two Phase 2b trials with results detailed at the company's April 29 Q1 print: VISTA (NCT06579092, 310 obesity patients, 26-week weight loss) and SOLSTICE (NCT06579105, 406 type-2 diabetes patients, 26-week HbA1c change vs semaglutide and placebo). AstraZeneca held back exact weight-loss numbers, framing the molecule as 'very competitive,' with full data scheduled for the American Diabetes Association meeting in June. The company committed to a comprehensive Phase 3 program targeting both weight-loss efficacy and outcome benefits, with monotherapy and fixed-dose combination programs anchored against the SYH2082 dual-agonist and LiquidGel monthly-dosing platform from the $18.5B CSPC Pharmaceuticals collaboration.
AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.